1 / 26

Preventing HIV & Fatal Opiate Overdose among Injection Drug Users

Preventing HIV & Fatal Opiate Overdose among Injection Drug Users. Scott Stokes Director of Prevention Services AIDS Resource Center of Wisconsin June 13, 2012. Topics for Today. HIV & HCV Overview of Harm Reduction Sterile Syringe Access Fatal Opiate Overdose.

isi
Télécharger la présentation

Preventing HIV & Fatal Opiate Overdose among Injection Drug Users

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Preventing HIV & Fatal Opiate Overdose among Injection Drug Users Scott Stokes Director of Prevention Services AIDS Resource Center of Wisconsin June 13, 2012

  2. Topics for Today • HIV & HCV • Overview of Harm Reduction • Sterile Syringe Access • Fatal Opiate Overdose

  3. Working Definition of Harm Reduction Harm Reduction: A set of practical, public health strategies designed to reduce the negative consequences of drug use and promote healthy individuals and communities.

  4. Key Principles of Harm Reduction • Designs & promotes public health interventions that minimize the harmful affects of drug use. • Understands drug use as a complex, multi-faceted issue that encompasses behaviors from severe abuse to total abstinence. • Meets people where they are in the course of their drug use

  5. Key Principles (continued) • Ensures that people who use drugs have a real voice in the creation of programs. • Affirms people who use drugs are the primary agents of change. • Empowers communitiesto share information and support each other

  6. Social and Environmental Factors • It does not attempt to minimize the real dangers associated with licit and illicit drug use, and how those issues impact our lives.

  7. Harm Reduction Practice Calls For • Non-judgmental, non-coercive provision of services • Low-threshold program models • Resources to people who use drugs

  8. Goals of Harm Reduction • Prevent disease Sterile syringe access to prevent HIV and hepatitis • Reduce mortality Overdose prevention with training and naloxone distribution; link to medical care and social services • Treatment for drug dependence Buprenorphine, Suboxone or Methadone Maintenance • Empowercommunities and reduce stigma Community organizing and engagement

  9. Sterile Syringe Access: History and Timeline • First started in Holland in response to hepatitis B outbreak in the 1980s • First legal program in United States started in Tacoma, Washington in 1988 • First Wisconsin program began in 1994 • Rooted in activism and advocacy

  10. Efficacy and Outcomes • Syringe access programs are the most effective, evidence-based HIV/HCV prevention tool for people who use drugs • Seven federally funded research studies found that syringe exchange programs are a valuable resource • In cities across the nation, people who inject drugs have reversed the course of the AIDS epidemic by using sterile syringes and harm reduction practices

  11. Key points in research: syringe exchange does not… • Syringe exchange does not encourage drug use • Syringe exchange does not increase crime rates • Syringe exchange does not increase needlestick injuries in the community

  12. Syringe Exchange Does…. • Syringe exchange reduces HIV infection. • Syringe exchange reduces risk for hepatitis C infection. • Syringe exchange programs link participants to drug treatment, medical care, housing, and other social services.

  13. Injection Drug Use: national scope • Estimates of current injection drug users in the United States range from 354,000 to over 1.3 million. • Injection drug use occurs in every socioeconomic and racial/ethnic group and in urban, suburban, and rural areas. • The majority of injection drug users are men, but between 1/4 and 1/3 of injection drug users are women.

  14. The NEED for Syringe Access & Harm Reduction • Over 8,000 people are newly infected with HIV every year due to syringe sharing. • In 2011, in Wisconsin, 285 people were newly infected with HIV, 22 (8%) due to syringe sharing. • Over 15,000 people are newly infected with hepatitis C every year due to syringe and equipment sharing. (2,027 confirmed cases in 2010)

  15. Demographics • African Americans account for over 50% of all AIDS cases attributed to injection drug use, while Latinos account for nearly 25%. • Among women, an estimated 61% of AIDS cases are due to injection drug use or the result of sexual contact with someone who contracted HIV through injection drug use. • Younger injection drug users generally become infected with hepatitis C within two years.

  16. Sterile Syringe Access Programs • Nearly 200 syringe exchange programs currently operate in 38 states, Puerto Rico, Washington DC. • Wisconsin has four syringe exchange providers ( ARCW, AIDS Network, 16th Street Community Health Clinic, Madison Health Department ) • Access includes: syringe exchange programs, over-the-counter pharmacy sales, syringe prescriptions, and secondary exchange (distribution informally through peer networks) • Endorsed by American Medical Association, American Public Health Association, US Conference of Mayors, among many other legal, medical, and policy institutions

  17. Syringe exchange program models • Storefront • Street-based (fixed sites; roving sites through mobile vans and/or walking teams) • Peer and secondary exchange through networks • Underground, unauthorized programs (operating under the radar)

  18. Opportunities and Challenges: the good news and bad news GOOD:Syringe exchange services are available in Appleton, Beloit, Eau Claire, Green Bay, Janesville, Kenosha, La Crosse, Madison, Milwaukee, Racine, Superior, Waukesha & Wausau. BAD: Staffing levels have remained the same. Many programs are poorly/under funded.

  19. ARCW’s LifePoint • Fixed site, mobile, delivery • No enrollment • No limits on supply’s • HIV/HCV testing offered to all • Monday – Saturday

  20. ARCW’s LifePoint2011 • Exchanged 1,504,181 syringes • 195 drug treatment referrals • 704 HIV tests (11 positives) • 274 HCV tests (56 positives) • 272,716 condoms distributed

  21. Materials • Syringes/needles • Cookers/cotton • Alcohol wipes • Antibiotic ointment • Tourniquets • Condoms

  22. Preventing Fatal Opiate Overdose • 85% of all overdoses are witnessed • Active drug users will respond • Naloxone (Narcan) reverses an overdose

  23. How Do We Respond to an Overdose? • Stimulate – can they be awakened • Call 911 • Airway • Rescue Breathing • Evaluate • Muscular Injection • Evaluate & Support

  24. ARCW’s Impact2011 • 728 IDU’s Trained • 519 Peer Rescues Reported • 85 Facilitated Referrals to Treatment

  25. Still A Long Way To Go • Expand Training • 911 Good Samaritan Law • Naloxone Shortage/Price Gouging

  26. Contact Information Scott Stokes Director of Prevention Services AIDS Resource Center of Wisconsin 445 S. Adams Street Green Bay, WI 54301 920-437-7400 ext. 106 scott.stokes@arcw.org

More Related